Kristin Jensen

The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron's top-selling eye drug Eylea, even as litigation continues.

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't silence questions about its commercial outlook.

The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.

The company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders.

The selling price is an indication that the FDA’s planned sunsetting of the rare pediatric disease voucher program may be pushing values higher, according to one analyst.

Elevidys sales have increased since the FDA chose to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving” treatment landscape.

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.